Favorable prognosis stage I–II Hodgkin’s disease: selected studies analyzing the radiation fields and dose, and the optimal chemotherapy.
| Trial . | Treatment Regimens . | # Pts. . | Outcome . | . | References . | |
|---|---|---|---|---|---|---|
| Abbreviations: RT, radiation therapy; STLI (S), subtotal nodal irradiation (splenic irradiation); CS, clinical stage; FFTF, freedom from treatment failure; FU, follow-up; IF, involved field; NS, nodular sclerosis histology; LP, lymphocyte predominance histology; MOPP, mechlorethamine, vincristine, procarbazine, prednisone; ABVD, doxorubicin, vinblastine, bleomycin, dacarbazine; Stanford V regimen, mechlorethamine, doxorubicin, vinblastine, prednisone, vincristine, bleomycin, VP-16; RFS, relapse free survival. | ||||||
| GHSG HD7 | A. EF RT 30 Gy (IF 40 Gy) | 305 | FFTF 75% | SV (5 years) 94% | 3 | |
| B. 2 ABVD + EF RT 30 Gy (IF 40 Gy) | 312 | 91%P < .0001 | 94%P = NS | |||
| SWOG #9133 | A. 3 (doxorubicin + vinblastine) + STLI (S) (36–40 Gy) | 165 | FFTF 94% | SV (3 years) 98% | 4 | |
| B. STLI (S) (36–40 Gy) | 161 | 81%P < .001 | 96%P = NS | |||
| EORTC/ GELA H7F | A. 6 EBVP + IF RT (36 Gy) | 168 | RFS 90% | SV (5 years) 98% | 5 | |
| B. STNI (S) | 165 | 81%P = .002 | 95% NS | |||
| EORTC/ GELA H8F | A. 3 MOPP/ABV + IF RT (36 Gy) | 271 | RFS 99% 99% | SV (4 years) | 6 | |
| B. STNI (S) | 272 | 80% 95%P < .0001 | P < .0186 | |||
| Stanford- V (favorabe CS IA-IIA HD) | Stanford V for 8 weeks + modified IF RT (30 Gy) | 65 | median FU = 16 month 3-years-FFP = 94.6% SV = 96.6% | 7 | ||
| EORTC H9F | A: 6 EBVP + IF RT (36 Gy) | 158 | FFTF overall 79% | |||
| B: 6 EBVP + IF RT (20 Gy) | 147 | |||||
| C: 6 EBVP (no RT) | 129 | Arm C: Closed because of high relapse rate | ||||
| GHSG HD10 | A. 2 ABVD + IF RT (30 Gy) | 204 | FFTF overall (24-month) = 97% | 8 | ||
| B. 2 ABVD + IF RT (20 Gy) | 210 | SV overall (24-month) = 99% | ||||
| C. 4 ABVD + IF RT (30 Gy) | 218 | |||||
| D. 4 ABVD + IF RT (20 Gy) | 215 | |||||
| 05.1998 — 01.2003 | ||||||
| Milan 1990–97 | A: 4 ABVD + STLI | 65 | FFP 97% | SV(5-years) 93% | 9 | |
| B: 4 ABVD + IFRT | 68 | 94% | 94% | |||
| GHSG HD13 | A. 2 ABVD + 30Gy IF RT | Started January 2003 | Open | |||
| B. 2 ABV + 30 Gy IF RT | ||||||
| C. 2 AVD + 30 Gy IF RT | ||||||
| D. 2 AV + 30 Gy IF RT | ||||||
| Trial . | Treatment Regimens . | # Pts. . | Outcome . | . | References . | |
|---|---|---|---|---|---|---|
| Abbreviations: RT, radiation therapy; STLI (S), subtotal nodal irradiation (splenic irradiation); CS, clinical stage; FFTF, freedom from treatment failure; FU, follow-up; IF, involved field; NS, nodular sclerosis histology; LP, lymphocyte predominance histology; MOPP, mechlorethamine, vincristine, procarbazine, prednisone; ABVD, doxorubicin, vinblastine, bleomycin, dacarbazine; Stanford V regimen, mechlorethamine, doxorubicin, vinblastine, prednisone, vincristine, bleomycin, VP-16; RFS, relapse free survival. | ||||||
| GHSG HD7 | A. EF RT 30 Gy (IF 40 Gy) | 305 | FFTF 75% | SV (5 years) 94% | 3 | |
| B. 2 ABVD + EF RT 30 Gy (IF 40 Gy) | 312 | 91%P < .0001 | 94%P = NS | |||
| SWOG #9133 | A. 3 (doxorubicin + vinblastine) + STLI (S) (36–40 Gy) | 165 | FFTF 94% | SV (3 years) 98% | 4 | |
| B. STLI (S) (36–40 Gy) | 161 | 81%P < .001 | 96%P = NS | |||
| EORTC/ GELA H7F | A. 6 EBVP + IF RT (36 Gy) | 168 | RFS 90% | SV (5 years) 98% | 5 | |
| B. STNI (S) | 165 | 81%P = .002 | 95% NS | |||
| EORTC/ GELA H8F | A. 3 MOPP/ABV + IF RT (36 Gy) | 271 | RFS 99% 99% | SV (4 years) | 6 | |
| B. STNI (S) | 272 | 80% 95%P < .0001 | P < .0186 | |||
| Stanford- V (favorabe CS IA-IIA HD) | Stanford V for 8 weeks + modified IF RT (30 Gy) | 65 | median FU = 16 month 3-years-FFP = 94.6% SV = 96.6% | 7 | ||
| EORTC H9F | A: 6 EBVP + IF RT (36 Gy) | 158 | FFTF overall 79% | |||
| B: 6 EBVP + IF RT (20 Gy) | 147 | |||||
| C: 6 EBVP (no RT) | 129 | Arm C: Closed because of high relapse rate | ||||
| GHSG HD10 | A. 2 ABVD + IF RT (30 Gy) | 204 | FFTF overall (24-month) = 97% | 8 | ||
| B. 2 ABVD + IF RT (20 Gy) | 210 | SV overall (24-month) = 99% | ||||
| C. 4 ABVD + IF RT (30 Gy) | 218 | |||||
| D. 4 ABVD + IF RT (20 Gy) | 215 | |||||
| 05.1998 — 01.2003 | ||||||
| Milan 1990–97 | A: 4 ABVD + STLI | 65 | FFP 97% | SV(5-years) 93% | 9 | |
| B: 4 ABVD + IFRT | 68 | 94% | 94% | |||
| GHSG HD13 | A. 2 ABVD + 30Gy IF RT | Started January 2003 | Open | |||
| B. 2 ABV + 30 Gy IF RT | ||||||
| C. 2 AVD + 30 Gy IF RT | ||||||
| D. 2 AV + 30 Gy IF RT | ||||||